Actium Biosystems LLC is engaged in the research and development of cancer treatments combining the expanding knowledge of cancer biology with the rapidly converging fields of nanotechnology, material science, and electromagnetic energy illumination. Through the application of advances in these and other areas, Actium seeks to develop more effective, safer, and less expensive cancer treatments.
The culmination of this work is the development of a new potentially disruptive platform technology; the Actium Cancer Treatment (ACT) System that uses externally generated magnetic energy to heat magnetic nanoparticles embedded in or adjacent to cancer tumors that in combination with radiation, chemotherapy, or immunotherapy produces a therapeutic benefit.
Actium is organized into six functional groups; Management, Accounting and Administration, Research and Development, Regulatory, Marketing and Reimbursement, and Finance.
To date we have retained twelve employees in these groups. To assist in our business development efforts we have retained expert consultants experienced in medical device and drug development, conducting medical laboratory research, securing FDA approval, and patent law. More information about each of these individuals is available by selecting the pictures above.
Finally, we work with various industry consultants who provide specialized services, including two FDA consultants, a medical device development consultant, and government grant consultant.
Actium has a highly experienced management team comprised of individuals who have each built successful businesses. Collectively this group has created over 10 individual successful companies in their careers. They have led complex project development efforts, assembled extensive business relationships, executed research and development efforts, organized and implemented large-scale project development transactions involving hundreds of professionals, created state legislative solutions
to address complex government policy business impediments, and were responsible for successfully raising over $250 million of financing.
Jessie Lai-Sim Au, PharmD, PhD
Distinguished University Professor
Pharmaceutics and Pharmaceutical Chemistry
Dr. Bruce F. Mackler, PhD.
Senior FDA Consultant
Dr. Edward M. Messing, MD
Professor of Urology, University of Rochester Medical Center
Dr. Michael O’Donnell, MD
Professor of Urology, Holden Cancer Center University of Iowa
Dr. Craig S. Rosenfeld, MD
Dr. Richard Willson PhD.
Professor of Biochemical Engineering, University of Houston